UroGen Pharma Ltd
Statements
Cash Flow
UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -33 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.5 | 13 | -2.7 | -3.5 | 2.6 | -6.0 | -9.6 | -8.1 | -9.3 | -10 | -18 | -15 | -13 | -26 | -36 | -24 | -25 | -21 | -27 | -19 | -18 | -20 | -24 | -24 | -17 | -22 | -26 | -20 | -17 | -13 | -32 | -24 | -28 | -14 | -42 | -40 | -42 | -38 | -45 | -33 | -159 | |
| 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 1.1 | 0.5 | 0.5 | 0.5 | 0.6 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 2.6 | |
| 0.5 | 0.6 | 0.3 | 1.6 | 2.2 | 2.3 | 4.5 | 7.7 | 9.5 | 8.9 | 7.4 | 7.2 | 7.2 | 8.1 | 7.6 | 7.1 | 6.8 | 6.5 | 6.2 | 6.0 | 5.5 | 5.4 | 2.9 | 2.8 | 2.4 | 2.4 | 2.3 | 2.2 | 2.2 | 2.6 | 2.8 | 3.6 | 3.5 | 3.3 | 3.1 | 2.7 | 3.0 | 3.1 | 4.6 | 5.3 | 16 | |
| – | 4.7 | 1.0 | 1.9 | 2.2 | 6.5 | 4.8 | 7.7 | 9.5 | 8.7 | 7.4 | 7.2 | 7.2 | 8.1 | 7.6 | 7.1 | 6.8 | 6.2 | 6.2 | 8.1 | 5.5 | 5.4 | 2.9 | 3.5 | 4.5 | 2.6 | 2.3 | 2.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.0 | -1.2 | 0.4 | 0.8 | 0.7 | 1.8 | -1.1 | 2.1 | 1.7 | 4.5 | -4.1 | 0.8 | 2.7 | 4.9 | -5.7 | 0.1 | -3.3 | 2.5 | -7.9 | -1.3 | -1.3 | -3.6 | -3.6 | -5.4 | 1.4 | 0.8 | -1.2 | -1.9 | -1.1 | 6.6 | -4.0 | 2.6 | -9.1 | 15 | -2.6 | 5.2 | -14 | -18 | -30 | -25 | -86 | |
| 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.3 | 0.7 | 0.2 | 0.3 | 0.1 | 0.2 | 0.2 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | |
| -0.1 | -0.1 | -0.1 | 0.0 | -0.1 | -36 | 36 | -0.2 | -0.3 | 0.0 | 0.0 | -142 | -13 | 9.3 | 13 | 18 | 13 | 49 | 15 | -31 | 11 | 9.1 | 14 | -0.2 | -35 | 23 | 6.3 | 3.7 | 0.4 | -11 | 14 | 12 | -107 | 61 | -26 | 28 | 31 | 28 | -21 | 1.7 | 40 | |
| – | 61 | 31 | -0.7 | -0.4 | 0.7 | 0.0 | 0.0 | – | 67 | 164 | 0.4 | 1.1 | 0.2 | 0.1 | 16 | 0.1 | 0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | 1.1 | 0.4 | 0.7 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | – | 71 | 71 | 71 | 71 | 0.0 | – | 25 | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | -1.9 | 65 | -0.4 | 63 | |
| 0.4 | -0.1 | -0.1 | 62 | -0.4 | -0.1 | 64 | 0.0 | 0.0 | 2.2 | 164 | 0.4 | 1.1 | 0.2 | 0.1 | 16 | 0.1 | 0.1 | 0.0 | 73 | -0.2 | 0.0 | 71 | -0.1 | 0.5 | 25 | 0.7 | 0.1 | 116 | 0.0 | 55 | 100 | 40 | 0.1 | 0.0 | 0.3 | 8.3 | 31 | 65 | 0.5 | 105 | |
| -3.3 | 13 | -2.9 | 59 | 2.1 | -42 | 90 | -8.4 | -9.6 | -7.9 | 146 | -156 | -24 | -16 | -23 | 9.9 | -12 | 28 | -12 | 23 | -8.0 | -11 | 60 | -24 | -52 | 27 | -19 | -16 | 99 | -24 | 36 | 89 | -95 | 47 | -68 | -11 | -2.6 | 21 | -0.8 | -31 | -14 | |
| -3.7 | 13 | -2.8 | -3.5 | 2.6 | -6.1 | -9.7 | -8.3 | -9.6 | -10 | -18 | -15 | -13 | -26 | -36 | -24 | -26 | -21 | -28 | -19 | -19 | -20 | -24 | -24 | -17 | -22 | -26 | -20 | -17 | -13 | -32 | -24 | -28 | -14 | -42 | -40 | -42 | -38 | -45 | -33 | -159 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.